News for hackers. Stuff that matters.
Re:India Supreme Court rejects Novartis' right to patent new... by shabda on Monday April 01, 2013 @12:05PM (#5473889)
If a private company has the duty to maximise profits, shouldn't a sovereign state have the duty to maximise the benefits to its citizens while fulfilling its minimum international treaty obligations.

The cost of gleevec/year is $36,000. The average per capita income is $1219[1]. If patented about 99% of people who need this drug can not afford it. Why should any state keep 99% of its people away from a life saving drug, if it doesn't have a legal obligation to do so.

Property rights are a means to an end. Even if all of Asia and Africa refused to recognize Novartis patents, they would still have enough incentive to continue developing cancer drugs.

1. http://en.wikipedia.org/wiki/Income_in_India

Re:India Supreme Court rejects Novartis' right to patent new... by windsurfer on Monday April 01, 2013 @01:38PM (#5474585)
Private companies don't need to have a duty to maximize profits. It's just incredibly common. See https://watsi.org/about#values
Re:India Supreme Court rejects Novartis' right to patent new... by tsotha on Monday April 01, 2013 @06:32PM (#5476361)
>If a private company has the duty to maximise profits, shouldn't a sovereign state have the duty to maximise the benefits to its citizens while fulfilling its minimum international treaty obligations.

They absolutely do. But that just shifts the argument to "what policy is the right one to maximize benefits to our citizens?"

>The cost of gleevec/year is $36,000. The average per capita income is $1219[1]. If patented about 99% of people who need this drug can not afford it. Why should any state keep 99% of its people away from a life saving drug, if it doesn't have a legal obligation to do so.

You could make the same argument in any country, including the US. And yet the system is the way it is for a reason.

>Property rights are a means to an end. Even if all of Asia and Africa refused to recognize Novartis patents, they would still have enough incentive to continue developing cancer drugs.

Would they? I wonder. It's possible eventually the grey market importation of unlicensed generics would make profits too small to justify the risk, and Novartis might decide yet another pecker perker would be a better investment than a cancer drug.

Re:India Supreme Court rejects Novartis' right to patent new... by kvb on Monday April 01, 2013 @12:57PM (#5474285)
Do you have a citation for that drug price (for Indians)? Another post cited a price more than an order of magnitude lower.
Re:India Supreme Court rejects Novartis' right to patent new... by bostonpete on Monday April 01, 2013 @01:01PM (#5474320)
The article says it costs about $2,600/month. Cheaper than $36,000/yr but not by an order of magnitude.
Re:India Supreme Court rejects Novartis' right to patent new... by mani27 on Monday April 01, 2013 @03:01PM (#5475139)
This drug is expensive at $2600/month. A fresher software engineer salary in IT company is about $500/month. Average Indian income is way low than that possibly less then $100/month.